Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study

Abstract

Background: Myopia-related maculopathy is one of the leading causes of blindness in the world. The prevalence of myopia has been reported as high as 90 % in some Asian countries. Therefore, controlling myopia progression is an urgent public issue. The purpose of this study is to evaluate the effects of topical atropine with different concentrations on intraocular pressure measurements and myopia progression in school-aged children in Taiwan.

Methods: Fifty-six myopic children were divided into three groups: 32 children were treated with 0.125 % atropine eyedrop; 12 of them were treated with 0.25 % atropine eye drop and another 12 served as a control group. IOP, auto-refractor and manifest refraction were measured at baseline and every 3 months following treatment for one year.

Results: There were no significant differences for the mean age, gender and baseline IOPs among the three groups. During the follow up period, no significant IOP difference was found among three groups. The change between final and baseline mean IOPs also revealed no significant differences: 0.54 mmHg, -1.28 mmHg, -0.33 mmHg for the 0.125 % atropine, 0.25 % atropine and control groups. The baseline mean spherical equivalent similarly did not differ significantly among groups but the control group showed a significant myopic progression compared to the 0.125 % atropine group 6 months after treatment, and persisted for one year. The change between final and baseline mean spherical equivalents were -0.05 D, 0 D, -1.05 D for the 0.125 % atropine, 0.25 % atropine and control groups, with both atropine-treated groups showing significant myopic retardation compared to the control group.

Conclusions: Topical use of low concentration atropine for one year does not induce ocular hypertension and is effective for retarding myopic progression. However, further large scale studies with longer follow up period is necessary to validate the long term safety and efficacy.

Trial registration: ISRCTN33002849 , 2016/01/19, retrospectively registered.

Keywords: Atropine; Intraocular pressure; Myopia.

Fig. 1

Mean intraocular pressure (IOP) in the three groups during the follow up period. *denotes significant difference compared to baseline mean IOP in the 0.25 % atropine group

Fig. 2

Mean spherical equivalent in the three groups during the follow up period. * indicates significant difference between 0.125 % atropine group and control group; ^# demonstrates significant difference between 0.25 % atropine group and control group